MedTrace Logo

Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914

NCT00456924 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2010-06-17

No results posted yet for this study

Summary

The purpose of the present study is to evaluate continuous administration of low doses of VA2914 for potential contraceptive activity and effects on the menstrual cycle and steroid hormone parameters.

Conditions

  • Contraception
  • Gynecologic Diseases

Interventions

DRUG

VA2914

Sponsors & Collaborators

  • HRA Pharma

    lead INDUSTRY

Principal Investigators

  • Philippe Bouchard, MD · Saint Antoine Hospital, Paris, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-31
Completion
2004-12-31

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00456924 on ClinicalTrials.gov